SCHEMBL7000474

SCHEMBL7000474

CC1Oc2ccc(N)cc2NC1=S

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.37
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
PDE3B Q13370 2/20 0.34
PDE3A Q14432 2/20 0.34
SMYD3 Q9H7B4 2/20 0.34
MAPT P10636 4/20 0.31
KDM4E B2RXH2 3/20 0.31
MEN1 O00255 3/20 0.31
GAA P10253 3/20 0.31
KMT2A Q03164 3/20 0.31
TDP1 Q9NUW8 2/20 0.31
APAF1 O14727 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PSMB8 P28062 1/20 0.31
MITF O75030 1/20 0.30
MAPK1 P28482 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
CA9 Q16790 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7000943 0.87 PARP1 (0.37) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL7988135 0.81 BRD4 (0.53) PARP1BRD4CREBBPMAPTMEN1
SCHEMBL496236 0.80 PARP1 (0.60) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL2104033 0.80 PARP1 (0.60) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL7984345 0.80 HSD17B10 (0.43) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL2917545 0.80 PARP1 (0.60) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL7711230 0.80 PARP1 (0.37) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL6995113 0.80 L3MBTL1 (0.35) PARP1BRD4CREBBPMEN1GAA
SCHEMBL7981172 0.78 PARP1 (0.35) PARP1BRD4CREBBPPDE3BPDE3A
SCHEMBL6998842 0.76 ACE2 (0.40) PARP1BRD4CREBBPMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed